Loading...
ONCY logo

Oncolytics Biotech Inc.NasdaqCM:ONCY Stock Report

Market Cap US$98.7m
Share Price
US$0.85
US$4.15
79.5% undervalued intrinsic discount
1Y81.8%
7D-4.5%
Portfolio Value
​
View

Oncolytics Biotech Inc.

NasdaqCM:ONCY Stock Report

Market Cap: US$98.7m

Oncolytics Biotech (ONCY) Stock Overview

A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. More details

ONCY fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Risk Analysis

Negative shareholders equity

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap ($99M)

+ 1 more risk

ONCY Community Fair Values

Create Narrative

See what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Oncolytics Biotech Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Oncolytics Biotech
Historical stock prices
Current Share PriceUS$0.85
52 Week HighUS$1.51
52 Week LowUS$0.33
Beta1.03
1 Month Change-24.11%
3 Month Change-19.81%
1 Year Change81.78%
3 Year Change-51.15%
5 Year Change-71.48%
Change since IPO-98.26%

Recent News & Updates

Seeking Alpha • Apr 25

Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths

Summary Oncolytics is narrowing Pelareorep development toward anal cancer and metastatic colorectal cancer, making its bull case more concrete. Pelareorep may turn “cold” tumors “hot,” potentially improving chemotherapy and checkpoint inhibitor responses across GI cancers. CRC data showed an unusually high 33% ORR versus 6%-11% historical SoC. This is why it received the FDA’s Fast Track designation. SCAC data showed encouraging response rates and complete responses. ONCY scheduled discussions with the FDA for a single-arm registrational pathway. I reckon ONCY’s dilution and clinical trial risks remain significant. Yet, the upcoming ER updates could help reframe ONCY around clearer regulatory timelines. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Apr 25

Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths

Summary Oncolytics is narrowing Pelareorep development toward anal cancer and metastatic colorectal cancer, making its bull case more concrete. Pelareorep may turn “cold” tumors “hot,” potentially improving chemotherapy and checkpoint inhibitor responses across GI cancers. CRC data showed an unusually high 33% ORR versus 6%-11% historical SoC. This is why it received the FDA’s Fast Track designation. SCAC data showed encouraging response rates and complete responses. ONCY scheduled discussions with the FDA for a single-arm registrational pathway. I reckon ONCY’s dilution and clinical trial risks remain significant. Yet, the upcoming ER updates could help reframe ONCY around clearer regulatory timelines. Read the full article on Seeking Alpha
Analysis Article • Sep 03

Is Oncolytics Biotech (NASDAQ:ONCY) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Mar 11

Oncolytics Biotech: Continuing To Justify The Negativity

Summary Oncolytics Biotech's main asset, pelareorep, shows mixed results in trials, with no definitive efficacy signals and ongoing financial struggles threatening operations. The GOBLET trial in pancreatic cancer continues, but key data readouts are not expected until late 2025, adding uncertainty. ONCY's financial situation is dire, with cash runway only into Q3 2025, raising serious concerns about their ability to fund operations. Given the high risk, low market cap, and lack of clear efficacy, I maintain a "Sell" rating and advise against investing in ONCY. Read the full article on Seeking Alpha

Shareholder Returns

ONCYUS BiotechsUS Market
7D-4.5%-1.6%-0.3%
1Y81.8%34.3%24.0%

Return vs Industry: ONCY exceeded the US Biotechs industry which returned 34.3% over the past year.

Return vs Market: ONCY exceeded the US Market which returned 24% over the past year.

Price Volatility

Is ONCY's price volatile compared to industry and market?
ONCY volatility
ONCY Average Weekly Movement11.1%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.1%

Stable Share Price: ONCY has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ONCY's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199829Jared Kellyoncolyticsbiotech.com

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.

Oncolytics Biotech Inc. Fundamentals Summary

How do Oncolytics Biotech's earnings and revenue compare to its market cap?
ONCY fundamental statistics
Market capUS$98.71m
Earnings (TTM)-US$33.29m
Revenue (TTM)n/a
0.0x
P/S Ratio
-3.0x
P/E Ratio

Is ONCY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ONCY income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$33.29m
Earnings-US$33.29m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.29
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ONCY perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/17 03:34
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oncolytics Biotech Inc. is covered by 19 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas LoeCantor Fitzgerald Canada Corporation
Wang ChongEdison Investment Research
Patrick TrucchioH.C. Wainwright & Co.